Atlas Venture Life Science Advisors, LLC Q3 2023 Filing

Filed November 13, 2023

Portfolio Value

$645.6M

Holdings

15

Report Date

Q3 2023

Filing Type

13F-HR

All Holdings (15 positions)

#	Stock	Shares	Value	% Portfolio	Type
1	IRONDisc Medicine, Inc.	2,745,335	$129.0M	19.98%
2	DAWNDay One Biopharmaceuticals, Inc.	7,608,394	$93.4M	14.46%
3	DYNDyne Therapeutics, Inc.	9,885,449	$88.6M	13.72%
4	KYMRKymera Therapeutics, Inc.	5,858,262	$81.4M	12.61%
5	THRDThird Harmonic Bio, Inc.	10,907,859	$69.7M	10.80%
6	REPLReplimune Group, Inc.	2,098,300	$35.9M	5.56%
7	VIGLVigil Neuroscience, Inc.	5,836,874	$31.5M	4.87%
8	GBIOGBXGeneration Bio, Co.	8,279,484	$31.4M	4.86%
9	AVTEAerovate Therapeutics, Inc.	2,039,249	$27.7M	4.29%
10	—Ikena Oncology, Inc.	5,018,178	$21.7M	3.37%
11	AKROAkero Therapeutics, Inc.	359,251	$18.2M	2.81%
12	—AvroBio, Inc.	4,541,381	$7.0M	1.08%
13	XLOXilio Therapeutics, Inc.	2,759,344	$5.8M	0.90%
14	DNTHDianthus Therapeutics, Inc.	236,979	$3.2M	0.50%
15	SPROSpero Therapeutics, Inc.	1,013,438	$1.2M	0.19%